Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epicardial Cardiac Fat Comparative Trial
NCT07297589Phase 3Recruiting
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in myocardial infarction (MI) (2 arms), sponsored by Instituto Mexicano del Seguro Social. Primary endpoint: Epicardial fat volume at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT07297589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297589.